These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37273452)

  • 61. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
    Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
    Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Paip1 Indicated Poor Prognosis in Cervical Cancer and Promoted Cervical Carcinogenesis.
    Li N; Piao J; Wang X; Kim KY; Bae JY; Ren X; Lin Z
    Cancer Res Treat; 2019 Oct; 51(4):1653-1665. PubMed ID: 31010277
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A microRNA-Messenger RNA Regulatory Network and Its Prognostic Value in Cervical Cancer.
    Liu J; Yang J; Gao F; Li S; Nie S; Meng H; Sun R; Wan Y; Jiang Y; Ma X; Cheng W
    DNA Cell Biol; 2020 Jul; 39(7):1328-1346. PubMed ID: 32456463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer.
    Zhang H; Yan T; Liu Z; Wang J; Lu Y; Li D; Liang W
    J Cell Biochem; 2018 Jan; 119(1):938-947. PubMed ID: 28681918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
    Wu J; Wang Y; Jiang Z
    J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Construction of a hypoxia-immune-related prognostic model and targeted therapeutic strategies for cervical cancer.
    Xie S; Ding B; Wang S; Zhang X; Yan W; Xia Q; Meng D; Shen S; Yu B; Liu H; Hu J; Wang S
    Int Immunol; 2022 Jul; 34(7):379-394. PubMed ID: 35561666
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.
    Yao H; Jiang X; Fu H; Yang Y; Jin Q; Zhang W; Cao W; Gao W; Wang S; Zhu Y; Ying J; Tian L; Chen G; Tong Z; Qi J; Zhou S
    Front Pharmacol; 2022; 13():870221. PubMed ID: 35662687
    [No Abstract]   [Full Text] [Related]  

  • 69. Upregulation of lncRNA CALML3-AS1 promotes cell proliferation and metastasis in cervical cancer via activation of the Wnt/β-catenin pathway.
    Liu CN; Zhang HY; Liu CL; Wang CC
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5611-5620. PubMed ID: 31298313
    [TBL] [Abstract][Full Text] [Related]  

  • 70.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
    Chong GO; Lee YH; Han HS; Lee HJ; Park JY; Hong DG; Lee YS; Cho YL
    Gynecol Oncol; 2018 Jan; 148(1):97-102. PubMed ID: 29153540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long non-coding RNA BLACAT1 promotes cell proliferation, migration and invasion in cervical cancer through activation of Wnt/β-catenin signaling pathway.
    Wang CH; Li YH; Tian HL; Bao XX; Wang ZM
    Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3002-3009. PubMed ID: 29863244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients.
    Wei H; Zhang JJ; Tang QL
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5587-5593. PubMed ID: 29271990
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Knockdown of long non-coding RNA LINC00518 inhibits cervical cancer proliferation and metastasis by modulating JAK/STAT3 signaling.
    Wang DW; You D; Dong J; Liu TF
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):496-506. PubMed ID: 30720156
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer.
    Chen S; Li K
    BMC Cancer; 2020 Sep; 20(1):924. PubMed ID: 32977766
    [TBL] [Abstract][Full Text] [Related]  

  • 76. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
    Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
    BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Worse Prognosis in Cervical Cancers.
    Cho U; Kim HM; Park HS; Kwon OJ; Lee A; Jeong SW
    PLoS One; 2016; 11(9):e0162623. PubMed ID: 27611086
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer.
    Xu F; Zou C; Gao Y; Shen J; Liu T; He Q; Li S; Xu S
    Front Immunol; 2022; 13():930488. PubMed ID: 36091054
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer.
    Liang Z; Li X
    Autoimmunity; 2021 Mar; 54(2):76-87. PubMed ID: 33596760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.